Throughout my life, I have developed a strong curiosity regarding biomedicine, oncobiology and neurobiology/neuroscience. During both my master and doctoral research I was interested in studying the cellular and molecular mechanisms associated with brain pathologies, namely gliomas and multiple sclerosis. At the moment, as well as during my PhD thesis (focused in inflammation-associated myelin damage), my scientific activity is based on oligodendrocyte and myelin biology, and multiple sclerosis (MS). My profound background and interests in the pathobiology of myelin-related diseases motivated me to join the Cellular Mechanobiology lab, where I am trying to understand the role of alterations in the biophysical properties and its effect in the signaling transduction, as well as its importance to oligodendrocyte development and myelin-associated processes, as (re)myelination, in a context of demyelinating situations, such as MS.
Since I started working in the field of mechabiology recently, I can not offer much expertise related with this scientific area. Nonethless, I can offer several skills concerning inflammation, oligodendrocytes and MS, as expertise in different models to study myelin-related processes and oligodendrocyte development, as well as expertise in different molecular biology techniques.
I am seeking to improve my skills concerning to the mechanobiology field, as much as possible, from the concepts part to the existing technologies and techniques to evaluate mechanical alterations and signalling transduction. In that sense, to be part of the EuroCellNet will allow me growth scientifically in this scientic field.
1. Barateiro A, Santos G, Afonso V, Brites D, Fernandes A (2015). Role of S100B on Oligodendrocyte Physiology and Pathology. Oligodendrocytes: Biology, Functions and Role in the Pathology of Diseases. Nova Science Publishers, ISBN: 978-1-63483-361-5
2. Santos G, Barateiro A, Gomes CM, Brites D, Fernandes A. Impaired oligodendrogenesis and myelination by elevated S100B levels during neurodevelopment. Neuropharmacology. 2018 ;129:69-83.
3. Pinheiro R, Braga C, Santos G, Bronze M, Jesus MJ, Moreira R, Brites D, Falcão AS. Targeting Gliomas: Can a New Alkylating Hybrid Compound Make a Difference?. ACS Chem Neurosci. 2017; 18;8(1):50-59.
4. Barateiro A, Afonso V, Santos G, Cerqueira JJ, Brites D, van Horssen J, Fernandes A. S100B as a Potential Biomarker and Therapeutic Target in Multiple Sclerosis. Mol Neurobiol. 2016; 53(6):3976-3991.
5. Gomes C, Santos G, Falcão AS, Brites D. Early differentiating astroglial mouse progenitors share common protein signatures with GL261 glioma cells. J Stem Cell Regen Biol 2016 2(2): 77-91.
6. Torrado E, Gomes C, Santos G, Brites D, Falcão AS. Directing mouse embryonic neurosphere differentiation towards an enriched neuronal population. Int J Dev Neurosci 2014; 37:94-9.
25–30 May 2020, Spetses Island, Greece